Key terms
About NVS
Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest NVS news
Apr 17
6:21am ET
Novartis announces data from the ALITHIOS study of Kesimpta
Apr 15
2:05pm ET
Novartis reports results from interim analysis of Phase 3 APPLAUSE-IgAN study
Apr 11
9:12am ET
MorphoSys board recommends shareholders accept Novartis offer
Apr 11
8:59am ET
MorphoSys Management, Supervisory board recommend Novartis takeover
Apr 11
7:05am ET
Arvinas enters exclusive strategic license agreement with Novartis for ARV-766
Apr 11
6:34am ET
Evercore expects Vera Therapeutics to trade up on Alpine acquisition news
Apr 07
6:51am ET
Novartis announces new data on twice-yearly Leqvio in ASCVD
Mar 22
7:34am ET
Novartis reports Fabhalta receives positive CHMP opinion
Mar 20
6:02am ET
BioNTech names Annemarie Hanekamp as Chief Commercial Officer
Mar 13
11:00am ET
European Stocks: Unnoticed Records, Overlooked Opportunities
Mar 13
8:45am ET
Largest borrow rate increases among liquid names
Mar 13
7:09am ET
Novartis acquires IFM Due
Mar 13
5:22am ET
Novartis downgraded to Neutral from Outperform at Oddo BHF
Mar 11
8:45am ET
Largest borrow rate increases among liquid names
Mar 08
8:45am ET
Largest borrow rate increases among liquid names
Mar 07
8:45am ET
Largest borrow rate increases among liquid names
Mar 04
6:34am ET
Novartis presets new data on Zolgensma
Mar 01
8:45am ET
Largest borrow rate increases among liquid names
Feb 29
11:27am ET
Olema Pharmaceuticals (NASDAQ:OLMA) Stock: Is There More Upside After a Remarkable Run in 2023?
Feb 23
5:18am ET
Novartis initiated with a Market Perform at BMO Capital
Feb 14
8:05am ET
Erasca announces two CTCSAs with Novartis for trametinib
Feb 07
11:01am ET
Biotech Alert: Searches spiking for these stocks today
Feb 06
1:48pm ET
MorphoSys tells Bloomberg STAT story ‘factually wrong’
Feb 06
11:52am ET
Novartis will ‘walk away from’ deal to buy MorphoSys, STAT’s Feuerstein says
Feb 06
5:17am ET
M & A News: Novartis (NYSE:NVS) Acquires MorphoSys in $2.9B Deal
Feb 05
4:59pm ET
Novartis to acquire MorphoSys for EUR 68 per share, or aggregate of EUR 2.7B
Feb 05
1:47pm ET
Cytokinetics weakness a buying opportunity, says Truist
Feb 05
1:11pm ET
MorphoSys could fetch $3B-$4B in a takeout, says Wells Fargo
Feb 05
10:20am ET
Novartis in lead to acquire MorphoSys, Reuters says
Feb 05
10:18am ET
Novartis in advanced talks to buy MorphoSys, Reuters says
Feb 01
6:16am ET
U.S. sends offers for drugs selected for price negotiations, NY Times says
No recent press releases are available for NVS
NVS Financials
Key terms
Ad Feedback
NVS Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
NVS Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range
